Objectives: To investigate the effectiveness of topical tacrolimus treatment on herpetic stromal keratitis (HSK) in a rat model. Methods: The development of HSK was monitored for 14 days after the inoculation of rats with herpes simplex type 1 virus. Rats that developed HSK were divided into four groups as follows: (1) topical antiviral treatment (control), (2) topical antiviral and 1% prednisolone acetate, (3) topical antiviral and 0.03% tacrolimus ointment, and (4) topical antiviral plus 0.1% tacrolimus ointment. After 14 days of treatment, the severity levels of HSK were scored and compared with the levels before the treatment. The expression of CD3, CD4, and CD8 was evaluated by flow cytometry. The development of the disease was evaluated clinically and histologically. Results: Significant improvement in vascularization was observed in the groups with the drug treatment in addition to the antiviral agent (P,0.05), but there was no obvious difference within groups 2, 3, and 4 in the vascularization severity. The regression of corneal edema was 8.05%6 6% in group 1, 25.17%614.55% in group 2 (P¼0.01), 36.40%621.69% in group 3 (P¼0.03), and 46.39%614.96% in group 4 (P¼0.00). A significant decrease in the number of inflammatory cells in the groups with the drug treatment was evaluated by immunohistochemical staining and confirmed by flow cytometry analysis. Conclusions: Topical tacrolimus treatment caused a significant decrease in corneal vascularization accompanied by a lower number of inflammatory cells in the experimental HSK corneal edema model. Therefore, topical tacrolimus has the potential to be used in the treatment of HSK.
H erpetic stromal keratitis (HSK) is a chronic recurrent inflammatory disease occurring due to infection by the herpes simplex type 1 virus (HSV-1). 1 Because of recurrences, the disease may cause visual morbidity associated with a wide range of sequelae because of corneal vascularization, irreversible stromal scarring, and lipid keratopathy. Herpetic stromal keratitis is believed to represent a T-cell-mediated immunopathologic basis 2 that primarily involves CD4 + and CD8 + cells. 2, 3 Vessels of neovascularization are more susceptible to leakage and contribute to blurred vision by allowing the escape of inflammatory cells. 4 After corneal vascularization is evident, it is difficult to manage HSK lesions, and patients need to be treated with topical steroids for a long period. If steroid treatment is kept short because of the side effects, then HSK recurrences occur, causing an increase in the overall HSK recurrence rate. 5 Thus, new alternative therapies are needed for the treatment of HSK.
Currently, much research reveals that alternatives to the steroid treatment of HSK, the use of nonsteroid anti-inflammatory drugs, implantation of amniotic membrane, and cyclosporine A were tested. [6] [7] [8] [9] [10] [11] Topical cyclosporine application was also shown to be effective in HSK treatment, and its effect is concentration dependent. 10 Tacrolimus, a potent immunosuppressive macrolide isolated from the soil fungus Streptomyces tsukubaensi, acts primarily by suppressing both B-cell and T-cell activation, T helper cellmediated responses, and the production of interleukin (IL)-2, such as cyclosporine A. As a result, both drugs inhibit the activation and proliferation of inflammatory cells. 12, 13 Both topical cyclosporine A and tacrolimus have effectively been used in treatments of ocular surface diseases, such as superior limbic keratoconjunctivitis, atopic keratoconjunctivitis, and penetrating keratoplasty. [14] [15] [16] [17] [18] Although it is 100 times more effective than cyclosporine, no significant systemic side effect was reported for the treatment by topical tacrolimus. 19 To the best of our knowledge, this is the first prospective study on the use of tacrolimus on HSK. In this study, we evaluated the effectiveness of topical tacrolimus on HSK in a rat model. We used immunohistochemistry (IHC), flow cytometry, and clinical approaches to evaluate the effects of different doses of topical tacrolimus.
MATERIALS AND METHODS

Animals
Seventy-two Wistar albino rats weighing 250 to 350 g and aging 6 to 8 weeks were used in this study. The animal studies were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and the research was approved by the Ethics Committee of Kocaeli University Medical Faculty.
Virus Production
Herpes simplex virus type 1 human strain stock was kindly provided by Ayhan Kubar, Professor of Medical Microbiology at Gulhane Military Medical Academy.
Virus stock is prepared using virus titer determined by performing a plaque assay in Vero cells. 20 Plaque-forming unit (PFU) was calculated by adding serial dilutions of recovered virus stock onto Vero cells grown in 24-well plates.
We inoculated 5 mL working solution including 1 · 10 6 PFU of HSV-1 onto rats' eyes, and the HSK was diagnosed clinically. 21 The causative agent was confirmed also by polymerase chain reaction (PCR) assay for the detection of HSV-1. Swab samples were collected for PCR, and they were sent to the laboratory with transport medium (UTM; Copan Diagnostics Inc., Brescia, Italy). DNA isolation was performed. Polymerase chain reaction assay for HSV-1 DNA was used for the confirmation of the causative agent. We inoculated the viruses on rats' eyes, and the HSK was diagnosed clinically; however, we needed to show the virus with microbiological diagnostic methods. Therefore, we performed PCR using the primers and probe as shown below.
The primer and probe sets targeting the DNA polymerase UL30 gene were used for the real-time TaqMan PCR method. The primers and probes used were as follows:
Sense primer: 59-CATCACCGACCCGGAGAGGGAC-39 Antisense primer: 59-GGGCCAGGCGCTTGTTGGTGTA-39 Probe sequence: CCGCCGAACTGAGCAGACACCCGCGC (Dye 6-FAM).
Reactions were run in 25-mL volumes containing 2 mL of sample DNA. The TaqMan PCR conditions were as follows: activation was 1 cycle of 95°C for 4 min and amplification and detection were 40 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec.
Positive cultures were identified as HSV-1 by PCR in both cell culture and rat samples.
Rat Herpetic Stromal Keratitis Model
For anesthesia, a combination of ketamine hydrochloride (50 mg/kg, Ketalar; Eczacıbaşı, Istanbul, Turkey) and xylazine hydrochloride (5 mg/kg, Rompun; Bayer, Istanbul, Turkey) was used. After instillation of 1 drop of 0.5% proparacaine hydrochloride (Alcaine; Alcon, Puurs, Belgium), corneas were scarified in 10 maneuvers with a 30-gauge needle until stroma was reached by horizontal and vertical moves under microscopic magnification (Topcon OMS 75; Topcon Medical Systems, Oakland, NJ). Five microliters of working HSV-1 stock was applied to the eyes within 10 sec, and then the eyelids were closed and massaged for 30 secs. Fourteen days after HSV-1 inoculation, 40 rats showed disease signs, and HSK levels were examined and evaluated.
Corneas that had HSK were divided into 4 groups of 10 animals each. Group 1 (control group) was treated with topical 3% acyclovir ointment (Zovirax; GlaxoSmithKline, Bridgewater, NJ) only 5 times a day; group 2 (steroid group) was treated with 3% acyclovir ointment 5 times a day and topical 1% prednisolone acetate drop (Pred Forte; Allergan, Irvine, CA) twice a day; group 3 (0.03% tacrolimus group) was treated with 3% acyclovir 5 times a day and 0.03% tacrolimus ointment (0.03% Protopic; Astellas Pharma Inc., Northbrook, IL) twice a day; and group 4 (0.1% tacrolimus group) was treated with 3% acyclovir ointment 5 times a day and 0.1% tacrolimus (0.1% Protopic; Astellas Pharma Inc.) twice a day.
On the 1st and 14th day of treatment, we evaluated and photographed the corneas in a blinded fashion under a microscope. The eyes were examined on these days of postinfection with a slitlamp biomicroscope (Kowa, Nagoya, Japan), and the clinical severity of keratitis of individually scored rat was recorded. In the photographs, the corneas of the rat to be evaluated were divided into 16 equal slices for scoring. The clinical lesion scores of HSK were described as 0, normal cornea; 1, mild haze; 2, moderate haze, iris visible; 3, severe haze, iris not visible; 4, severe haze and corneal ulcer; and 5, corneal rupture. In the 1st and 14th day of treatment we scored the edema, difference was calculated in percentages.
Angiogenic activity was scored by the number and length of newly developed vessels. A score of 0 was assigned for no neovascularization, 1 was assigned to the length within 20% of the radius, 2 for lengths from 20% to 40% of the radius, 3 for lengths from 20% to 40% of the radius, 4 for lengths from 40% to 60% of the radius, 5 for lengths from 60% to 80% of the radius, and 6 for the lengths from 80% to 100% of the radius. When several vessels had extensive branching, we took the longest vessel as a standard score. So, we used the scale in the cornea divided into 80 parts ( Fig. 1) , and for each animal, we calculated the corresponding percentage, and the scale was expressed as a percentage. These percentages were used for further comparisons.
Immunohistological Examination
The animals were killed by an overdose (150 mg/kg) of intracardiac ketamine. Enucleation was performed to the eyes of each subject before immunohistological examination. The enucleated eyes were then fixed in 4% paraformaldehyde for 30 min, and corneas were removed and were subjected to 30 additional minutes to fixation. Paraformaldehyde-fixed tissue blocks were washed, dehydrated in ethanol, and embedded into paraffin blocks. From these paraffin tissue blocks, 6-mm-thick tissue samples were sliced and immunohistochemically stained with CD3, CD14, or CD68 using monoclonal antibodies. Blocking serum that we used was obtained from Santa Cruz Biotechnology (Heidelberg, Germany).
FIG. 1.
Representative scale used in angiogenic activity scoring.
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Stained samples were evaluated and imaged for the presence of inflammatory cells. To identify cellular markers, cells were subjected to IHC staining as described previously. 22 
Flow Cytometry Analysis
Randomly selected samples (five corneas per group) were subjected to flow cytometry analyses. The corneas of rats were removed and transferred into 50-mL conical tubes (BD Falcon Biosciences, San Jose, CA) containing 100 units/mL of penicillin, 100 mg/mL of streptomycin (P-S; Gibco Invitrogen Corporation, San Diego, CA), CaCl 2 -and MgCl 2 -free Hank's balanced salt solution (HBSS 1·; Gibco Invitrogen Corporation). The cornea samples were then washed 5 to 6 times with 15 mL of HBSS containing 100 units/mL of penicillin and 100 mg/mL of streptomycin, after the transfer into 100 · 20 mm sterile culture dishes. Finally, the samples were transferred into clean dry petri dishes. The cornea samples were then diced with a curve-tipped scissors to a size of 1 mm 3 . On the cornea pieces, collagenase (0.5 mg/mL prepared in RPMI and supplemented with 10% FBS, 10 mg/mL of gentamicin, and 5 mg/mL of HEPES) was added, and the samples were incubated at 37°C. After incubation for 2 hr, 20 mL of RPMI 1640 was added to the samples, and the samples were centrifuged at 400g for 10 min to remove the supernatant. To each remaining pellet, 10 mL of CAM was added for resuspension, and samples were centrifuged again at 400g for 5 min. This step was repeated twice, and the pellet, formed after final centrifugation, was resuspended in 1 mL of RPMI 1640 and passed through a series of filters (first from a 70-mm filter and then from a 40-mm filter; BD Falcon Biosciences). After a final round of centrifugation, the supernatant was discarded, and the pellet was resuspended in staining buffer and was analyzed by flow cytometry instrument.
To prepare for reading in the flow cytometer, the cells were centrifuged at 500g for 5 min, the supernatant was discarded, and 0.5 mL of stain buffer was added for resuspension. The resuspended cells were then aliquoted into 5-mL tubes (BD Falcon Biosciences) at the portions of 100 mL per tube. To each tube, one of the following was added with respect to the cell markers intended to be analyzed: (1) T-lymphocyte cocktail (CD3, CD4, and CD8) (BD Pharmingen, San Diego, CA), (2) rat compensation set (BD Pharmingen), (3) CD45, and (4) control for CD45. The tubes were incubated for 30 min before the addition of 500 mL of staining buffer, and flow cytometry analysis was performed with FACSCalibur (BD Biosciences, San Jose, CA). All of the antibodies were obtained from Becton Dickinson. The data were analyzed with CellQuest software (BD Biosciences), and the forward and side scatter profiles allowed us to gate out of debris and dead cells.
Statistical Analysis
Results were given as mean6SD. Statistical analysis was performed using software SPSS version 13.0 (SPSS Inc., Chicago, IL). A Mann-Whitney U test was used to evaluate the differences between the controls and treated eyes, and a Kruskal-Wallis test was used to evaluate the differences within the treatment groups. A P value less than 0.05 was considered significant.
RESULTS
Clinical scores were 21.8066.05 in control group, 22.0069.11 in the steroid group, 22.567.41 in the 0.03% tacrolimus group, and 19.2566.67 in the 0.1% tacrolimus group at 14 days after corneal HSV-1 inoculation. This variation was taken into consideration when the animals were divided into the four groups.
Clinical Evaluation of Herpetic Stromal Keratitis
At the first day of treatment, the average corneal neovascularization score was 45.3625.6 for group 1, 35.6619.7 for group 2, 39.2618.1 for group 3, and 40.1617.3 for group 4. No significant difference was observed in the average intensity of corneal vascularization among the groups at the onset of the treatment. However, a statistically meaningful improvement was observed in vascularization in the groups 2, 3, and 4 (P,0.05) at the 14th day (Fig. 2) . At the 14th day of treatment, the average corneal neovascularization score was 39.8624. (Fig. 3) . Thus, corneal neovascularization was significantly reduced by the treatment with tacrolimus (P,0.05). The average corneal neovascularization regression rate for group 1 (the control group) was 14.3%64.9%, for group 2 it was 38.5%622.2%, for group 3 it was 34.2%614.1%, and for group 4 it was 62.5%616.6%.
The average corneal edema regression rate for group 1 (the control group) was 8.05%65%, for group 2 (steroid group) it was 25.07%614.05%, for group 3 (0.03% tacrolimus group) it was 36.05%621.09%, and for group 4 (0.1% tacrolimus group) it was 46.09%614.06% (Fig. 4) .
A significant decrease was observed in corneal edema in the 0.1% tacrolimus group when it was compared with the 0.03% tacrolimus and steroid groups (P,0.05). The difference between the 0.03% tacrolimus and steroid group was not that significant (P.0.05). When the groups 2, 3, and 4 were compared with the control group, a significant decrease was observed in corneal edema formation (P,0.05).
Immunohistological Analysis
The expression of CD3, CD14, and CD68 was evaluated between groups (Fig. 5 ). There was a significant decrease in the expression of CD3, CD14, and CD68 in groups 2, 3, and 4 when compared with the control group. Group 4 showed a dramatic decrease.
The average CD3 expression level for group 1 (the control group) was 56.14%611.22%, for group 2 (steroid group) it was 36.61%66.44% (P¼0.01), for group 3 (0.03% tacrolimus group) it was 30.12%69.46% (P¼0.01), and for group 4 (0.1% tacrolimus group) it was 14.14%66.21% (P¼0.00). When 0.1% tacrolimus and 0.03% tacrolimus groups were compared with the steroid group, the P values were found to be 0.00 and 0.42, respectively. The expression level of CD68 was evaluated among the groups. There was a meaningful decrease in the expression of CD68 only in the 0.1% tacrolimus group when compared with the control group. The average CD68 expression level for group 1 (the control group) was 45.41%66.09%, for group 2 (steroid group) it was 35.97%6 7.08% (P¼0.69), for group 3 (0.03% tacrolimus group) it was 28.42%612.21% (P¼0.09), for group 4 (0.1% tacrolimus group) it was 15.01%68.62% (P¼0.01). When the 0.1% tacrolimus and 0.03% tacrolimus groups were compared with the steroid group, the P values were 0.00 and 0.42, respectively. The expression level of CD14 was evaluated among the groups. The average CD14 expression level for group 1 (the control group) was 72.62%6 3.99%, for group 2 (steroid group) it was 35.43%66.22%
Eye & Contact Lens Volume 42, Number 3, May 2016
Tacrolimus on Herpetic Stromal Keratitis (P¼0.00), for group 3 (0.03% tacrolimus group) it was 37.99%6 9.34% (P¼0.00), and for group 4 (0.1% tacrolimus group) it was 10.32%63.83% (P¼0.00). When the 0.1% tacrolimus and 0.03% tacrolimus groups were compared with the steroid group, the P values were found to be 0.00 and 0.42, respectively.
Flow Cytometry Analysis
Comparison of the percentage of cells according to the flow cytometric analysis of cells from the cornea is shown in Figure 6 . Figure 7 demonstrates flow cytometric data as plots of several cells expressing the CD markers. The average CD3 level for the control group was 25.52%62.25%, for the corticosteroid group it was 24.37%60.91% (P¼0.04), for group 3 it was 11.94%60.64% (P¼0.01), and for group 4 it was 1.77%60.64% (P¼0.01). When the 0.1% tacrolimus and 0.03% tacrolimus groups were compared with the corticosteroid group, the P values were found to be 0.00 for both.
The average CD4 level for the control group was 22.40%61.22%, for the corticosteroid group it was 10.75%61.43% (P¼0.04), for group 3 it was 11.66%61.82% (P¼0.01), and for group 4 it was 1.62%60.76% (P¼0.01). When the 0.1% tacrolimus and 0.03% tacrolimus groups were compared with the corticosteroid group, the P values were found to be 0.00 and 0.35, respectively.
The average CD8 level for the control group was 22.15%6 1.40%, for the corticosteroid group it was 8.17%63.90% (P¼0.00), for group 3 it was 11.60%62.47% (P¼0.01), and for group 4 it was 2.12%61.02% (P¼0.01). When the 0.1% tacrolimus
FIG. 2. Images from the first day of treatment (A-D) and day 14th of the treatment (E-H). The control group (A and E), the corticosteroid group (B and F), 0.03% tacrolimus group (C and G), 0.1% tacrolimus group (D and H).
FIG. 3.
Comparison of corneal vascularization score among the groups. When groups 2, 3, and 4 were compared with the control group, a significant decrease was observed. There was no significant difference among groups 2, 3, and 4 when intergroup comparisons were made. *P.0.05; **P,0.05.
FIG. 4.
The average corneal edema regression rates. *P.0.05; **P,0.05.
and 0.03% tacrolimus groups were compared with the corticosteroid group, the P values were found to be 0.01 for both comparisons.
DISCUSSION
The results of our study demonstrate that topical 0.03% tacrolimus is as effective as steroid treatment in HSK model, whereas 0.1% tacrolimus treatment was significantly more effective than steroid treatment.
Ocular HSV infection can result in corneal scarring and vascularization of the eye, resulting blindness throughout the individual's life. 23 Corneal neovascularization is a milestone in the pathogenesis of HSK; molecules inhibiting new vessel formation limit the lesions' severity. 24 In this study, 0.1% tacrolimus slightly, but not significantly, improved corneal neovascularization in comparison with the steroid and the control groups. Consistent with our observations, control of neovascularization by tacrolimus has been demonstrated previously using the experimental corneal neovascularization model 25 or in the retina 26 using the streptozotocin-induced diabetic retinopathy model. In HSK, the CD4 + T-lymphocyte subset, T helper 1-type, is the chief mediator with a supplementary role for Th17 cells orchestrating the extravasation and activation of neutrophils. 24, 27 The neutrophils appear to be involved in corneal injury. Also, Langerhans cells and macrophages, secreting the proinflammatory cytokines IL-1 and tumor necrosis factor (TNF)-a, are crucial mediators. 28 Tacrolimus inhibits T-cell proliferation and decreases T-cell-derived cytokines by blocking the function of enzyme calcineurin. 29 As a result, blockade leads to inhibition of the Th1-type cytokines IL-2 and interferon-g, which results in lymphocytes producing less TNF-a, hence suppression of this inflammatory response. Additionally, tacrolimus inhibits the production of a number of proangiogenic factors, such as vascular endothelial growth factor-A, fibroblast growth factor, epidermal growth factor, histamine, platelet-derived growth factor, matrix metalloproteinases, MMP-9 and MMP-13, prostaglandin E2, IL-1, IL-6, and IL-17, and hypoxia-inducible factor that are involved in corneal neovascularization, consequently reducing the severity of HSK. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] In this study, clinically significant differences were observed in animals treated with 0.1% tacrolimus, whereas in animals treated Tacrolimus on Herpetic Stromal Keratitis with steroid and 0.03% tacrolimus, no clinically significant differences were found. Barequet et al. 40 investigated the therapeutic effect of a topical administration of 0.03% tacrolimus in comparison with 0.1% dexamethasone in a mouse model with acute allergic conjunctivitis. Consistent with our study, they reported that the clinical efficacy of topical 0.03% tacrolimus was similar to that of 0.1% dexamethasone for acute allergic conjunctivitis. In our study, we found that steroid and 0.03% tacrolimus treatment resulted in equal improvements in corneal edema, whereas 0.1% tacrolimus treatment seems to be most effective in the management of HSK edema.
Previous studies 41, 42 demonstrate the role of IL-17 in HSK model and concluded that IL-17 may contribute to immune inflammatory events mediated by CD4 + T cells in the recurrent infection mouse model of HSK. In addition, the clinical study by Yago et al. 43 has also shown that tacrolimus also inhibited expression of IL-17 or TNF-a, and they suggest a therapeutic effect on T-cell-associated diseases.
Yoon et al. 10 noted that cyclosporine and tacrolimus have a similar effect, and cyclosporine also has different effects in different dosages. Tacrolimus shares several immunosuppressive properties with cyclosporine A, although it is known to be 10 to 100 times more potent in this regard. Previous studies on the use of tacrolimus ointment in atopic eyelid disease have also shown good levels of response and improvement in conjunctivitis symptoms without adverse events. [14] [15] [16] The main findings of this study suggest that 0.1% tacrolimus ophthalmic solution offers an efficient option for the treatment of HSK, although the study group is small in number and the course of the treatment may be considered short. Despite the small sample size and randomization, unequal distribution of lesions was one of the limitations of this study. Also, this study is short term; therefore, it is unclear whether in the long run it can really replace steroids, which show similar efficacy in reducing inflammation. The clinical use of steroids can develop serious side effects after continuous use in the long run; normally, their short-term usage does not develop any significant issues. Thus, further long-term studies are needed to address the long-term safety and efficacy.
Topical steroids remain as a joint point for the suppression of corneal edema and neovascularization in HSK treatment. Steroid therapy can lead to serious side effects in long-term use, such as increase in intraocular pressure and cataract formation. The improvements provided by treatment with tacrolimus ointment highlight the advantageous role of tacrolimus. In the presence of all this information, tacrolimus may be used in patients failing to respond to steroids or with the risk of a high rate of complications because of chronic use of steroids. The interpretation of data for immunohistochemical analysis and flow cytometry analysis revealed decreased T lymphocytes, macrophages, monocytes, and leucocytes in treatment groups in accordance with clinical evaluation. In addition to this finding, we also report a decrease in CD8 and CD3 levels in 0.1% tacrolimustreated subjects.
Tacrolimus administration markedly reduced HSK lesion progression and the degree of corneal neovascularization, and it was associated with a reduced influx of T cells and neutrophils and the production of proinflammatory cytokines, chemokines, and proangiogenic molecules. Thus, tacrolimus therapy may represent a novel approach to suppressing HSV-induced ocular immunoreaction instead of steroids, while also avoiding corneal scarring.
In our study, the effect of tacrolimus on HSK was shown to be because of the suppression of cytokines, which ultimately cause a decrease in macrophage chemotaxis. As reported by others, direct activation of T cells can be inhibited by tacrolimus treatment. It will be important to understand how the activation of T cells resulting in HSK is mediated at the molecular level.
In conclusion, 0.1% tacrolimus treatment is more effective then 1% prednisolone treatment in HSK. In addition, there was no clearcut difference between the uses of 0.03% tacrolimus and 1% prednisolone acetate in HSK treatment.
When we compare the acyclovir only-treated group with the steroid plus 0.03% tacrolimus-received group, we noticed that there was a meaningful decrease in T lymphocyte levels. CD4-positive T lymphocyte levels did not show a change when the 0.03% tacrolimus-received group was compared with the steroidreceived group. Based on these findings, we can conclude that the use of 0.03% tacrolimus is as effective as the use of 1% prednisolone on HSK treatment without the complications seen with steroids. In the future, topical tacrolimus might be a promising treatment alternative in both treating stromal keratitis and preventing recurrences of herpetic keratitis.
